polaryx.comCrawled Nov 10, 2026
Polaryx Therapeutics is approved to study PLX-200, a novel therapy, in three clinical trials, including SOTERIA, a Phase 2 basket trial for rare lysosomal storage disorders, and pivotal trials for CLN2 and CLN3.
Polaryx has a diversified potentially disease-modifying pipeline composed of small molecule and gene therapies.
Polaryx’s small molecule drug candidates target lysosomal biogenesis, brain inflammation, and neuronal cell death.
The company’s leadership team has experience guiding drug development toward commercialization.
Accelerating the availability of treatment options for patients and families living with Lysosomal Storage Disorders.
Batten Disease presents as seizures and / or vision failure followed by progressive motor dysfunction and cognitive decline.
Polaryx Therapeutics is developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders.
Polaryx Therapeutics activates Boys Town National Research Hospital in Nebraska as the first site for its **SOTERIA Phase 2 basket trial** of **PLX-200**, a treatment targeting **four rare pediatric lysosomal storage disorders**. The site has begun **patient screening** as the company progresses toward the first patient dosing.
Nov 2026investors.polaryx.comNews article
Polaryx Therapeutics names Dr. Will Charlton as its new Chief Medical Officer. He joins with over 15 years of experience in rare disease and pediatric drug development, including prior CMO and clinical development roles. His appointment strengthens the company’s leadership in advancing specialized therapies.
Sep 2026investors.polaryx.comNews article
Polaryx Therapeutics secures **$10 million in private placement equity financing** to advance its **SOTERIA Phase 2 basket trial**. The funding, closed on **May 28, 2026**, supports the company’s clinical development efforts in oncology. The proceeds follow a PIPE (private investment in public equity) transaction.
May 2026investors.polaryx.comNews article
Polaryx Therapeutics names **Dr. Lisa Bollinger** as its new **Chief Medical Officer**. The late-stage biotech company specializes in treatments for lysosomal storage disorders. Bollinger brings clinical leadership to advance Polaryx’s drug pipeline.
Oct 2025EIN PresswireNews article
